New York, Aug. 18, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Digital Pathology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by product, type, application, end user, and geography,” the report highlights trends prevailing in the market and factors driving its growth. The growth of the digital pathology market is attributed to the rising adoption of digital pathology to enhance lab efficiency and growing applications of digital pathology in drug development and companion diagnostics. However, the high cost of digital pathology systems and the shortage of skilled professionals to operate these systems may hinder the market growth.
Get Sample PDF Copy of Digital Pathology Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPHE100000855/
Digital Pathology Market Report Scope & Strategic Insights:
| Report Coverage | Details |
| Market Size Value in | US$ 0.95 Billion in 2022 |
| Market Size Value by | US$ 1.89 Billion by 2028 |
| Growth rate | CAGR of 12.1% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
| No. of Pages | 226 |
| No. Tables | 197 |
| No. of Charts & Figures | 83 |
| Historical data available | Yes |
| Segments covered | Product, Type, Application, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Digital Pathology Market: Competitive Landscape and Key Developments
Koninklijke Philips N.V.; Nikon Corporation; Perkin Elmer, Inc.; Indica Labs; 3DHISTECH Ltd.; Hamamatsu Photonics K.K.; F. Hoffmann-La Roche Ltd; Visiopharm A/S; Glencoe Software, Inc.; and Danaher Corporation are among the leading companies in the digital pathology market. The market is anticipated to flourish with the development of new innovative products by market players.
Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPHE100000855/
In October 2021, Koninklijke Philips N.V. launched its next-generation digital pathology solution—IntelliSite—to assist pathologists in diagnosing and creating care pathways.
In July 2021, Danaher Corporation announced its next-generation Aperio GT 450 DX scanner that supports DICOM Imaging and shows compatibility with PACS; the product enables the tighter integration of digital pathology imaging into diagnostic pathway.
In June 2020, Koninklijke Philips N.V. collaborated with Proscia to accelerate and encourage the adoption of digital pathology in laboratories. The agreement provides Proscia an exclusive right to natively utilize Philips’ iSyntax image format with its Concentriq digital pathology platform.
In April 2021, Koninklijke Philips N.V. collaborated with Ibex to promote their digital pathology and artificial intelligence (AI) solutions to hospitals, health networks, and pathology labs across the world. This helped the company to provide objective, reproducible results, and boost diagnostic confidence.
Have a question? Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100000855
In April 2021, Danaher Corporation entered into a partnership with Paige to expand its access to computational pathology products for clinical and translational research. The agreement brings Paige’s AI-enabled research software for tumor detection, grading, and quantification to Leica Biosystems' digital pathology platform in North American and European countries.
The North America digital pathology market is further segmented into the US, Canada, and Mexico. The market growth in the region is attributed to the growing number of initiatives to promote the use of digital pathology for enhanced disease diagnosis and advanced pathology practice. The US Food and Drug Administration (FDA) has provided clearance for the use of digital pathology and whole slide imaging (WSI) systems in primary diagnosis. In April 2017, the first WSI system for digital pathology was approved for primary diagnostics in the US. This has helped pathologists in digitizing the workflow, and in gathering, storing, and transferring patent data from remote places. The second digital pathology system was authorized for marketing in the US in 2019. As a result, 100% of labs in the US are likely to go digital in the near future. The FDA approval of WSI systems has allowed research institutes in the US to increase their efficiency and workflow. The American Cancer Society (ACS) estimated 1,898,160 new cancer cases and 608,570 cancer-related deaths in the US in 2021. Digital pathology solutions play a vital role in cancer diagnosis and drug discovery, which supports the market growth in North America.
Use of Digital Pathology in Cancer Diagnosis Boosts Market Growth:
The World Health Organization (WHO) has reported cancer as the first leading cause of death in people of age less than 70 in 183 countries and the fourth leading cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types caused ~10 million deaths in 2020 in the world. The use of digital pathology allows the in-depth diagnosis of tumors. Traditional pathology services can only help locate the tumor cells, which makes it difficult to share the cases for a second review. Digital cancer diagnosis typically involves scanning conventional glass slides to get successive images that are digitally united into a single, whole image that replicates information on the glass slide. The pictures from associated clinics/hospitals or labs are combined to provide an integrated picture of each unique cancer condition to the pathologists.
Avail Lucrative DISCOUNTS on “Digital Pathology Market” Research Study: https://www.theinsightpartners.com/discount/TIPHE100000855/
Companies are launching new digital pathology tools and technologies for cancer detection. In January 2021, Roche launched the CE-IVD automated digital pathology algorithms that are capable of uPath HER2 Dual ISH image analysis and uPath HER2 (4B5) image analysis for breast cancer diagnosis, which also helps healthcare providers determine the best treatment strategy for each patient. Artificial intelligence (AI) is used in image analysis algorithms to assist pathologists in achieving quick and accurate patient diagnoses. Further, in May 2022, Hartford HealthCare launched a clinical research and innovation platform in collaboration with Ibex Medical Analytics, a pioneer in AI-powered cancer diagnostics, to help clinicians deliver accurate diagnoses and enhanced care for patients with breast cancer. Thus, the use of digital solutions in the diagnosis of cancer is increasing with technological developments, thereby fueling the digital pathology market growth.
Digital Pathology Market: Segmental Overview
Based on product, the digital pathology market is segmented into scanner, software, storage, and communication systems. The scanner segment is further bifurcated into integrated and standalone. The scanner segment held the largest market share in 2021; however, the software segment is expected to register the highest CAGR during the forecast period.
Based on type, the digital pathology market is bifurcated into human pathology and veterinary pathology. The human pathology segment held a larger market share in 2021 and is expected to register a higher CAGR during the forecast period.
Based on application, the digital pathology market is segmented into drug discovery, disease diagnostics, teleconsultation, and training & education. The drug discovery segment held the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.
Directly Purchase Premium Copy of Digital Pathology Market Growth Report at: https://www.theinsightpartners.com/buy/TIPHE100000855/
Based on end user, the digital pathology market is segmented into pharma & biotech companies, hospitals, and academics. The pharma & biotech companies segment held the largest market share in 2021 and is estimated to register the highest CAGR during the forecast period.
Browse Adjoining Reports:
Pathology Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Technology (Immunoassays Technology, Disease Diagnostics, Clinical Chemistry, Drug Discovery and Development, Forensic Diagnostics); Application (Clinical Chemistry, Hematology, Immunoassays Technology, Microbiology, Molecular Diagnostics); End User (Diagnostics laboratories, Forensic Laboratories, Academic Institutes, Contract Research Organizations, Pharmaceutical and Biotechnology Companies) and Geography
Anatomic Pathology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Service (Instruments, Consumables, and Services), Application (Disease Diagnosis, Drug Discovery and Development, and Others), and End User (Hospitals, Research Laboratories, Diagnostic Laboratories, and Others) and Geography
Whole Slide Imaging Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Hardware, Software, and Service), Application (Telepathology, Cytopathology, Immunohistochemistry, and Hematopathology), and End User (Hospital, Pharmaceutical and Biopharmaceutical Companies, Laboratories, and Academic Research Institute)
Histology and Cytology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Cytology, Histology); Test Type (Microscopy Tests, Molecular Genetics Tests, Flow Cytomtery); End User (Hospitals/Clinics, Biopharmaceutical Companies, Academia, Other End Users)
Diagnostic Labs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Lab Type (Single/Independent Laboratories, Hospital-Based Labs, Physician Office Labs, And Others), Testing Services [Physiological Function Testing (ECG, Echo, X-ray, Endoscopy, CT, MRI, and Others), General and Clinical Testing, Esoteric Testing, Specialized Testing, Non-invasive Prenatal Testing, COVID-19 Testing, and Others], Revenue Source (Healthcare Plan Operators and Insurers, Out-of-Pocket, and Public System)
Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Area (Oncology, Infectious diseases, Genetic testing, Cardiac diseases, Immune system disorders, and Others); Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing (NGS), In Situ Hybridization, DNA Microarray, and Others); Product and Services (Assays and Kits, Instruments, Services and Software); End User (Hospitals and Clinics, Diagnostic Laboratories, Research and Academic Institutes, and Others) and Geography
Laboratory Developed Test Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Clinical Biochemistry, Critical Care, Hematology, Microbiology, Molecular Diagnostics, Immunology, and Others) and Application (Academic Institutes, Clinical Research Organizations, Hospitals Laboratory, Specialty Diagnostic Centers, and Others)
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/digital-pathology-market
